SCHEDULE: Bank of America Discloses Travere Therapeutics Stake
Beneficial Ownership Filing
Bank of America Corporation has updated its beneficial ownership filing for Travere Therapeutics, Inc., reporting a significant stake.
Summary
- Bank of America Corp /DE/ has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Travere Therapeutics, Inc. common stock.
- As of September 30, 2026, Bank of America Corp /DE/ beneficially owns 6,810,705 shares, representing 7.1% of the class of securities.
- This ownership is held across various subsidiaries, including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware.
- The filing indicates shared voting power for 6,379,726 shares and shared dispositive power for 6,697,284 shares.
- The reporting person certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new strategic or financial performance information.
Positives
- Bank of America's updated filing provides transparency regarding its investment in Travere Therapeutics.
- The ownership stake of 7.1% indicates a significant institutional investor's interest.
Negatives
- The filing does not provide any new financial performance data or strategic updates for Travere Therapeutics.
- The information is purely a disclosure of beneficial ownership, offering no insight into the company's operational health.
Risks
- The filing itself does not introduce new risks but reflects the existing market risks associated with Travere Therapeutics' stock.
- Potential for future changes in beneficial ownership by Bank of America could impact market dynamics.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Travere Therapeutics' future performance.
Management Comments
- The reporting person certifies that the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. This filing indicates Bank of America's continued or established position as a significant holder in the biotechnology sector, specifically within Travere Therapeutics.
Stakeholder Impact
- Shareholders: Increased transparency on institutional ownership may influence investor sentiment.
- Management: Awareness of significant institutional holdings can impact strategic discussions and governance considerations.
Next Steps
- Continued monitoring of Bank of America's beneficial ownership in Travere Therapeutics.
- Observation of any future amendments to Schedule 13G filings by Bank of America or other institutional investors.
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Date of Event Which Requires Filing of this Statement (Reporting period end date for share count). |
| 2026-11-02 | Date of issuer's Form 10-Q disclosing outstanding share count. |
| 2026-11-16 | Date of filing of the Schedule 13G amendment. |
Keywords
Travere Therapeutics, Bank of America, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.